4 December 2015  - Amgen believes this submission is the first adalimumab biosimilar application submitted to the EMA and represents Amgen's first biosimilar to be submitted for approval in the European Union.

For more details, go to: http://www.amgen.com/media/news-releases/2015/12/amgens-first-biosimilar-marketing-authorization-application-submitted-to-european-medicines-agency-for-abp-501/